D-0555-2024 Class II Ongoing

Recalled by Eugia US LLC — East Windsor, NJ

FDA drug recall D-0555-2024 was initiated by Eugia US LLC on May 23, 2024 and is designated Class II. Reason for recall: Failed Impurities/Degradation Specifications: impurity sulfonic acid adduct of dexamethasone phosphate results were above spec. The recall status is ongoing. Affected quantity: 70,125 vials.

Recall details

Product Type
Drugs
Report Date
Jun 26, 2024
Initiation Date
May 23, 2024
Voluntary/Mandated
Voluntary: Firm initiated
Product Quantity
70,125 vials

Product description

Dexamethasone Sodium Phosphate injection USP, 120mg per 30mL (4mg/mL), 30 mL Multiple-Dose Vial, Rx only, Distributed by: AuroMedics Pharma LLC, 279 Princeton-Hightstown Rd. E. Windsor, NJ 08520, Made in India, NDC 55150-239-30

Reason for recall

Failed Impurities/Degradation Specifications: impurity sulfonic acid adduct of dexamethasone phosphate results were above spec.

Distribution pattern

USA Nationwide

Code information

Lot#: 3DS23001, 3DS23004, Exp 6/30/2024; 3DS23009, 3DS23011, Exp 7/31/2024

Source

Dataset
openFDA drug recall enforcement reports
FDA record
This recall in openFDA (JSON)
Enforcement Report
Search FDA's Enforcement Report for D-0555-2024
openFDA file date
Nov 10, 2026
Loaded by RegDataLab
Nov 11, 2026

These dates say when openFDA published the data file and when RegDataLab last loaded it.

Source: openFDA record for D-0555-2024. Report a data issue: hello@regdatalab.com.